| 王元英.脑力静胶囊联合艾司西酞普兰治疗女性更年期抑郁症疗效分析.[J].中南医学科学杂志.,2022,(4):602-605. |
| 脑力静胶囊联合艾司西酞普兰治疗女性更年期抑郁症疗效分析 |
| Efficacy of Naolijing capsules combined with escitalopram oxalate decoction on female menopausal depression |
| 投稿时间：2021-12-23 修订日期：2022-02-20 |
| DOI：10.15972/j.cnki.43-1509/r.2022.04.035 |
| 中文关键词: 脑力静胶囊 艾司西酞普兰 更年期抑郁症 单胺类神经递质 性激素 女性 |
| 英文关键词:Naolijing capsules escitalopram oxalate climacteric depression monoamine neurotransmitter sex hormone female |
| 基金项目: |
|
| 摘要点击次数: 250 |
| 全文下载次数: 307 |
| 中文摘要: |
| 目的研究脑力静胶囊联合艾司西酞普兰治疗女性更年期抑郁症的疗效。方法将180例女性更年期抑郁症患者随机均分为观察组和对照组。对照组给予艾司西酞普兰治疗,观察组在对照组基础上给予脑力静胶囊治疗。比较两组汉密尔顿抑郁量表(HADM)、匹兹堡睡眠质量量表(PSQI)、世界卫生组织生存质量测定量表简表(WHOQOL-BREF)和治疗不良反应量表(TESS)评分。观察治疗前后单胺类神经递质及性激素水平变化。结果观察组治疗有效率高于对照组(P＜0.05)。观察组治疗后2、4、6、8周HADM评分低于对照组(P＜0.05)。治疗8周后,两组PSQI评分、促卵泡激素(FSH)、促黄体生成素(LH)均降低,且观察组低于对照组(P＜0.05)；WHOQOL-BREF评分、5-羟色胺(5-TH)、去甲肾上腺素(NE)及雌二醇(E2)均升高,且观察组高于对照组(P＜0.05)。观察组的不良反应发生率及TESS评分低于对照组(P＜0.05)。结论脑力静胶囊可提高艾司西酞普兰治疗更年期抑郁的临床疗效,改善患者的睡眠质量和生活质量,且能够有效调节单胺类神经递质及性激素水平,安全性高。 |
| 英文摘要: |
| To study the efficacy of Naolijing capsule combined with escitalopram in the treatment of female climacteric depression. Methods180 patients with climacteric depression were randomly divided into observation group and control group. The control group was treated with escitalopram, and the observation group was treated with Naolijing capsule on the basis of the control group. The treatment period was 8 weeks. The scores of Hamilton Depression Scale (HADM), Pittsburgh Sleep Quality Scale (PSQI), World Health Organization short form of quality of life (WHOQOL-BREF) and treatment emerge symptom scale (TESS) were compared between the two groups before treatment and 2,4, 6 and 8 weeks after treatment. The levels of monoamine neurotransmitters and sex hormones were observed before and after treatment. ResultsThe effective rate of the observation group was higher than that of the control group(P＜0.05). The HADM score of the observation group was lower than that of the control group at 2,4, 6,8 weeks after treatment(P＜0.05). After 8 weeks of treatment, the WHOQOL-BREF scores, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in both groups were decreased, and the observation group was lower than the control group(P＜0.05). After 8 weeks of treatment, PSQI scores, 5-hydroxytryptamine (5-TH), norepinephrine (NE) and estradiol (E2) in the two groups were all increased, and the observation group was higher than the control group(P＜0.05). The incidence of adverse reactions and Tess in the observation group were lower than those in the control group(P＜0.05).ConclusionNaolijing capsule can improve the clinical efficacy of escitalopram in the treatment of climacteric depression, improve the sleep quality and quality of life of patients, and can effectively regulate the levels of monoamine neurotransmitters and sex hormones with high safety. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|